Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

HeadaTerm (TM): The Cost Would Not Add Pain to Migraine Patients

WAT Medical Enterpsise Ltd.
Posted on: 28 Jul 17

PR Newswire

VANCOUVER, Canada, July 28, 2017

VANCOUVER, Canada, July 28, 2017 /PRNewswire/ -- Cost Can be a Major Roadblock in Migraine Therapy

The team from migraine.com conducted a survey in 2016 titled: "Migraine in America" with the goal to gain a better understanding of the challenges faced by migraine patients. Over 3,900 people completed the 145-question survey.

The results show that:

  • Over 36% of the patients spent over $1,000 per year on migraine related treatments.
  • 64% of the patients have avoided therapy because of the cost.
  • 62% of the patients asked their doctors for cheaper prescriptions.
  • 50% of the patients skipped entire dosages to make their prescriptions last longer.

The impact of migraine on one's life can be overwhelming and far-reaching, negatively affecting personal relationships, ability to work or to attend school.

HeadaTerm Principle

HeadaTerm uses none-invasive external Trigeminal Nerve Stimulation (eTNS) technology that introduces precise electric impulses from the user's forehead to act on the supratrochlear nerves and reduce the migraine signals transmitted. The device avoids any drug effects, making it appropriate a wide range of users. eTNS has been clinically used for migraine and other conditions for over 40 years and was proven to be safety and effective.

What HeadaTerm contributed is making the therapy affordable - the device is low cost and it reduces the consume of medications. HeadaTerm is particularly helpful for sufferers with frequent migraine. The usage of medications would be reduced and the patient's quality of life to be improved. 

The product design is usability-based. Very portable design makes the therapy available at any place any time. LED light and buzzer indicates the status of device and keeps communicating with user. Easy shutter. Attached mirror helps user to position device. Arc-shaped device match easily with forehead.

HeadaTerm has medical level standard. It's CE-certified medical device to prevent and treat primary headache. It is estimated to be approved by FDA and Health Canada by early 2018. The manufacturer, WAT Medical, is certified to the ISO medical standard.

Low Cost Solution

HeadaTerm costs $29.00 per device. One device contains 21 rounds of standard therapies; each therapy lasts 20 minutes. HeadaTerm is designed to be an affordable innovative technology that provides access to a drug-free treatment for primary headaches.

For more information, please visit WAT Medical Enterprise Ltd.'s website at www.watmedical.com or email info@watmedical.com

References:

1. https://www.ncbi.nlm.nih.gov/pubmed/16095269
2. http://www.who.int/healthinfo/global_burden_disease/projections2004/en/
3. https://migraine.com/infographic/the-hidden-cost-of-care/

View original content:http://www.prnewswire.com/news-releases/headaterm-tm-the-cost-would-not-add-pain-to-migraine-patients-300495929.html

SOURCE WAT Medical Enterpsise Ltd.

PR Newswire
www.prnewswire.com

Last updated on: 28/07/2017

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.